Market Overview

UPDATE: Leerink Reiterates Outperform on BioMarin on Positive Cancer Drug Test Results

Share:
Related BMRN
Benzinga's Top Upgrades, Downgrades For August 17, 2017
Wall Street's M&A Chatter From July 26: Biomarin, Sigma Designs, Colgate-Palmolive, Markel-State National

In a report published on Monday, Leerink analyst Joseph Schwartz reiterated an Outperform rating on BioMarin (NASDAQ: BMRN) and maintained a $70.00 price target on the release of its full Phase 1/2 data on poly ADP-ribose polymerase (PARP) inhibitor BMN 673 for the treatment of solid tumors. These treatments showed good responses in BRCA cancer and breast cancer patients.

In the announcement, BioMarin said that drug response rates in patients exceeded the 30 percent threshold, this might be an underestimation because many patients haven't received the maximum tolerated dose.

According to Bloomberg data, BioMarin has 17 Buy ratings and 7 Holds. Prior to Monday, shares of the the stock gained 27 percent YTD. Shares are down about 7.8 percent at the time of publication. BioMarin closed Friday at $62.70.

Latest Ratings for BMRN

DateFirmActionFromTo
Oct 2017Morgan StanleyMaintainsOverweight
Sep 2017RBC CapitalInitiates Coverage OnSector Perform
Sep 2017PiperJaffrayAssumesNeutralOverweight

View More Analyst Ratings for BMRN
View the Latest Analyst Ratings

Posted-In: Joseph Schwartz LeerinkAnalyst Color Price Target Reiteration Analyst Ratings

 

Related Articles (BMRN)

View Comments and Join the Discussion!
Loading...

Partner Center

Loading...